Jacksonville Defective Drug Attorney

Pharmaceutical manufacturers operate under a legal and regulatory framework that holds them to strict standards, but those standards fail more often than the public realizes. When a drug causes harm due to a design flaw, a manufacturing error, or a failure to adequately warn patients and physicians about known risks, the injured person has legal recourse under Florida product liability law. A Jacksonville defective drug attorney at Gillette Law, P.A. represents clients who have suffered serious injuries from prescription drugs, over-the-counter medications, and medical devices, pursuing full compensation from the parties responsible for putting a dangerous product on the market.

How Defective Drug Claims Are Categorized Under Florida Law

Florida product liability law recognizes three distinct theories of defect, each of which applies differently to pharmaceutical cases. A design defect claim argues that the drug itself is inherently dangerous because of the way it was developed, meaning every unit produced carries the same unreasonable risk. A manufacturing defect claim applies when a specific batch or lot was contaminated, mislabeled, or improperly compounded during production. A failure to warn claim, sometimes called a marketing defect, arises when the drug’s labeling did not adequately communicate risks that the manufacturer knew or should have known about.

Failure to warn claims are by far the most common category in pharmaceutical litigation. Drug companies have an ongoing duty to update their labeling when post-market surveillance reveals new safety signals, and the FDA’s regulations require prompt reporting. When a company delays updating its warning label, or buries a critical risk in fine print that does not reflect the severity of the danger, it opens itself to liability. Florida courts have recognized this duty consistently, and it forms the backbone of many defective drug lawsuits filed in the state.

One aspect of defective drug law that surprises many clients is the “learned intermediary doctrine.” Under this doctrine, drug manufacturers typically discharge their duty to warn by informing the prescribing physician rather than the patient directly. However, this defense is not absolute. When a manufacturer markets a drug directly to consumers through advertising, or when the manufacturer knew that physicians were not being given adequate safety information, Florida courts have declined to apply the doctrine. Attorney Charles J. Gillette, Jr. examines whether this defense applies in each individual case before litigation strategy is determined.

What Must Be Established to Succeed in a Pharmaceutical Liability Case

Proving a defective drug claim requires more than showing that a patient took a medication and suffered a bad outcome. The plaintiff must establish that the drug was defective in one of the recognized legal categories, that the defect existed when the drug left the manufacturer’s control, and that the defect was the proximate cause of the specific injuries claimed. This causal link is where many pharmaceutical cases are won or lost, because drug companies routinely argue that the plaintiff’s condition stems from their underlying illness rather than from the medication itself.

Causation in these cases is almost always a battle of expert witnesses. The plaintiff’s legal team must retain qualified pharmacologists, toxicologists, or physicians who can connect the drug’s mechanism of action to the specific injury. Defense experts will argue alternative causes, pre-existing conditions, or statistical improbability. Federal courts applying Florida law and state courts alike require that expert testimony meet established standards of scientific reliability, which means the quality of expert selection and preparation directly affects the outcome.

Documents obtained through discovery often become the most powerful evidence in a defective drug case. Internal communications, clinical trial data, adverse event reports submitted to the FDA, and marketing materials can reveal what the manufacturer knew, when they knew it, and whether that information was disclosed honestly. Gillette Law, P.A. has represented clients in complex civil litigation for more than two decades, and the firm understands how to pursue comprehensive discovery against well-funded corporate defendants.

Federal Preemption and Its Limits in Florida Drug Injury Cases

Drug companies defending product liability claims frequently raise federal preemption as a threshold defense. The argument is that because the FDA approved the drug and its labeling, state law failure-to-warn claims are preempted by federal law. The U.S. Supreme Court addressed this issue in Wyeth v. Levine (2009), holding that FDA approval does not automatically preempt state tort claims. Manufacturers retain the ability to strengthen their warning labels without prior FDA approval under what is called the Changes Being Effected (CBE) regulation, and a failure to use that mechanism when new safety data emerged can support a state law claim.

The preemption analysis is more complex for generic drug manufacturers. In PLIVA, Inc. v. Mensing (2011), the Supreme Court held that generic manufacturers cannot independently change their labels because they are required by federal law to maintain labeling identical to the brand-name drug. This creates a significant legal split depending on whether the plaintiff took a brand-name or generic version of the drug. Florida plaintiffs who took generic medications may face additional hurdles in pursuing failure-to-warn claims, though design defect and manufacturing defect claims may still be viable depending on the facts.

Mass Tort Litigation and How Jacksonville Cases Often Proceed

Many defective drug claims are handled as part of multidistrict litigation (MDL), a federal procedural mechanism that consolidates cases from across the country before a single judge for pretrial proceedings. Florida plaintiffs with defective drug claims may find their cases transferred to an MDL court in another jurisdiction, though individual trials, if they occur, typically return to the plaintiff’s home district. The Middle District of Florida, which covers much of the state, has seen pharmaceutical cases proceed through this structure in recent years.

Participation in an MDL does not mean a plaintiff loses individual control over their case. Settlement decisions remain personal, and bellwether trials, which are test cases selected to help assess the overall litigation, can significantly affect settlement values for all plaintiffs in the pool. Having counsel who understands how MDL dynamics affect individual case valuation is critical. Gillette Law, P.A. approaches each client’s case with attention to how the broader litigation landscape may affect their specific recovery, without treating any client as a number in a spreadsheet.

For cases that do not enter federal MDL proceedings, Florida state court in Duval County handles pharmaceutical product liability claims. The Duval County Courthouse is located at 501 West Adams Street in Jacksonville. Florida’s statute of limitations for product liability claims is generally four years from the date the injury was discovered or reasonably should have been discovered, under Florida Statute Section 95.11(3). Missing this deadline typically bars the claim entirely, regardless of its merits.

Damages Available to Defective Drug Injury Victims

Compensation in a pharmaceutical liability case can include medical expenses, both those already incurred and reasonably anticipated future costs for ongoing treatment, monitoring, or corrective procedures. Lost wages and diminished earning capacity are recoverable when the drug-related injury affects a person’s ability to work. Florida law also allows recovery for pain and suffering, physical impairment, and other non-economic harm that flows from the injury.

Punitive damages are available in Florida product liability cases where the manufacturer’s conduct was particularly egregious, specifically where evidence shows that the company knowingly concealed safety information or acted with conscious disregard for patient welfare. Florida Statute Section 768.72 imposes procedural requirements before punitive damage claims can be added to a lawsuit, requiring a reasonable evidentiary basis shown to the court. This is a step Gillette Law, P.A. evaluates carefully when the underlying facts support it.

Common Questions About Defective Drug Claims in Florida

Does FDA approval mean a drug cannot be the basis of a lawsuit?

The law says FDA approval does not grant immunity from civil liability, and the Supreme Court confirmed this in Wyeth v. Levine. In practice, Florida courts regularly permit defective drug cases to proceed even when the drug received full FDA approval, particularly failure-to-warn claims where post-approval safety data was not reflected in labeling updates.

What if my doctor prescribed the drug and knew about some risks?

The law provides that a manufacturer’s duty to warn runs to the physician under the learned intermediary doctrine. In practice, however, this defense breaks down when the physician was not given accurate or complete information by the manufacturer’s own disclosures. If the warning provided to your doctor omitted material risks, that omission can still support a claim even if your doctor was generally aware of some side effects.

How does it matter whether I took a brand-name or generic version of the drug?

Federal law requires generic manufacturers to mirror the brand-name label, which limits their ability to independently update warnings. As a result, failure-to-warn claims against generic manufacturers face significant preemption challenges under federal law. Whether other theories like manufacturing defect remain viable depends heavily on the specific facts of the case.

How long do I have to file a defective drug lawsuit in Florida?

Florida’s statute of limitations for product liability claims is four years, running from discovery of the injury. In practice, determining exactly when the discovery clock started is frequently disputed. Delaying consultation with an attorney risks losing the ability to pursue the claim at all, because the four-year window cannot be extended by simply being unaware of the drug connection.

Can I still pursue a claim if the drug has since been recalled?

A recall actually strengthens a case by demonstrating that the manufacturer or the FDA determined the drug posed an unreasonable risk. The recall does not automatically establish liability, but it is powerful evidence that a defect existed. The plaintiff must still prove causation, meaning that the specific defect at issue caused the specific injury they suffered.

What if I signed a consent form before taking the medication?

Informed consent forms address the risks that are known and disclosed at the time of signing. They do not shield a manufacturer from liability for risks that were not disclosed or were actively concealed. In practice, courts have declined to treat these forms as blanket waivers of product liability claims.

Representing Clients Across the Jacksonville Region and North Florida

Gillette Law, P.A. represents clients throughout the greater Jacksonville area and the surrounding region, including residents of Riverside, Southside, Arlington, Mandarin, and the Beaches communities along the Atlantic coast. The firm also serves clients in Orange Park and other Clay County communities to the southwest, as well as those in St. Augustine and the broader St. Johns County area. North of the Florida state line, the firm’s representation extends into Brunswick, Georgia, and surrounding coastal Georgia communities. Whether a client is located near the St. Johns Town Center corridor, in the neighborhoods surrounding Beach Boulevard, or farther out in Nassau County or Baker County, distance has not been a barrier to receiving the same careful attention that Gillette Law, P.A. has provided to clients throughout Florida and Georgia for more than two decades.

Speak with a Jacksonville Drug Injury Lawyer About Your Case

Gillette Law, P.A. offers free initial consultations, and the firm handles personal injury and product liability cases on a contingency fee basis, meaning no legal fee is charged unless compensation is recovered. Given that Florida’s four-year product liability statute of limitations begins running at discovery of the injury, an early case evaluation matters for preserving your options. Contact Gillette Law, P.A. to schedule a consultation with a Jacksonville defective drug attorney who will assess the specific facts of your case and explain how Florida product liability law applies to your situation.